Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia

Purpose: We determine the long-term efficacy and safety of the UroLume stent as minimally invasive treatment for external detrusor-sphincter dyssynergia in spinal cord injured men. Materials and Methods: A total of 160 spinal cord injured men with a mean age plus or minus standard deviation of 36.3 ± 12.1 years (range 16 to 74) were prospectively treated with an endoprosthesis at 15 centers as part of the North American UroLume trial for external detrusor-sphincter dyssynergia. Urodynamic parameters, including voiding pressure, residual urine volume and bladder capacity, were compared before treatment and at 1, 2, 3, 4 and 5 years after treatment. Results: Mean voiding pressure was 75.1 ± 28.2 cm. water before treatment in the 160 patients, and 37.4 ± 23.9 at year 1 in 97, 39.5 ± 22.2 at year 2 in 84, 42.6 ± 27.3 at year 3 in 61, 46.3 ± 33.2 at year 4 in 57 and 44.2 ± 28.9 cm. at year 5 in 41 after stent insertion (p <0.001). Residual urine volume decreased after stent placement and was maintained throughout the 5-year followup (p <0.001). Mean cystometric capacity remained constant from 269 ± 155 before insertion to 337 ± 182 ml. 5 years later (p = 0.17). Hydronephrosis and autonomic dysreflexia improved or stabilized in most patients with functioning stents. Stent explant was necessary in 24 patients (15%), of whom 4 (16.7%) had another stent implanted. Conclusions: The UroLume stent demonstrates long-term safety and efficacy for the treatment of external detrusor-sphincter dyssynergia. The outcome was similar in men with and without previous sphincterotomy.